Bilaketaren emaitzak - Torben Rixecker

  • Erakusten 1 - 2 emaitzak -- 2
Findu emaitzak
  1. 1
    Optimization of rituximab for the treatment of DLBCL (I): dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL

    Optimization of rituximab for the treatment of DLBCL (I): dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL nork Niels Murawski, Michael Pfreundschuh, Samira Zeynalova, Viola Poeschel, Mathias Hänel, Gerhard Held, Norbert Schmitz, Andreas Viardot, Christian Schmidt, Michael Hallek, Mathias Witzens‐Harig, Lorenz Trümper, Torben Rixecker, C. Zwick

    Argitaratua 2014
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  2. 2
    TNF-related apoptosis-inducing ligand, interferon gamma-induced protein 10, and C-reactive protein in predicting the progression of SARS-CoV-2 infection: a prospective cohort study

    TNF-related apoptosis-inducing ligand, interferon gamma-induced protein 10, and C-reactive protein in predicting the progression of SARS-CoV-2 infection: a prospective cohort study nork Sina A. Tegethoff, Guy Danziger, Dennis Kühn, Charlotte Kimmer, Thomas Adams, Lena Heintz, Carlos Metz, Katharina Reifenrath, Rebecca Angresius, Sebastian Mang, Torben Rixecker, André Becker, Jürgen Geisel, Christophe Jentgen, Frederik Seiler, Matthias Reichert, Franziska Fröhlich, Sascha Meyer, Jürgen Rissland, Sebastian Ewen, Gudrun Wagenpfeil, Katharina Last, Sigrun Smola, Robert Bals, Frank Lammert, Sören L. Becker, Marcin Krawczyk, Philipp M. Lepper, Cihan Papan

    Argitaratua 2022
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:

Bilaketa egiteko lanabesak: